Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline

This guideline details procedures for the manufacture and evaluation of human serum pools for cholesterol measurement.
NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and healthcare services.

**PUBLICATIONS**

An NCCLS document is published as a standard, guideline, or committee report.

**Standard** A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

**Guideline** A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

**Report** A document that has not been subjected to consensus review and is released by the Board of Directors.

**CONSENSUS PROCESS**

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus- "proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

**Proposed** An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

**Tentative** A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

**Approved** An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS’s established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

**COMMENTS**

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

**VOLUNTEER PARTICIPATION**

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation.
Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline

Abstract

Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline (C37-A) outlines procedures for selecting, processing, and combining donor units to prepare frozen serum pools which are commutable among multiple methods for serum cholesterol measurement. The guideline also addresses issues related to the evaluation of the pooled materials. The manufacture and evaluation of two levels of serum cholesterol pools prepared according to this guideline are described. The appendix includes a summary of the results from the pilot study conducted to evaluate the scientific basis of this guideline.

This guideline will provide information to develop reference materials which can be useful to manufacturers of in vitro diagnostic (IVD) reagents, systems, and quality control products in establishment of calibration (or assigned values) for their products. Additionally, these reference materials can be beneficial to proficiency testing agencies, as well as end users in the clinical laboratory as tools to independently assess performance (and trueness) of procedures for the routine measurement of serum cholesterol.

Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline

Volume 19  Number 25

Gary L. Myers, Ph.D., Chairholder
John H. Eckfeldt, M.D., Ph.D.
Neil Greenberg, Ph.D.
Jacob B. Levine, M.B.A.
W. Gregory Miller, Ph.D.
Donald A. Wiebe, Ph.D.
Proposed Guideline

May 1998

Approved Guideline

November 1999
Committee Membership

Area Committee on Clinical Chemistry and Toxicology

Basil T. Doumas, Ph.D.
Chairholder
Medical College of Wisconsin
Milwaukee, Wisconsin

W. Gregory Miller, Ph.D.
Vice-Chairholder
Virginia Commonwealth University
Richmond, Virginia

Subcommittee on Cholesterol Reference Material Specifications

Gary L. Myers, Ph.D.
Chairholder
Centers for Disease Control and Prevention
Atlanta, Georgia

John H. Eckfeldt, M.D., Ph.D.
Fairview - University Medical Center
Minneapolis, Minnesota

Neil Greenberg, Ph.D.
Ortho Clinical Diagnostics
Rochester, New York

Bill Haden
Reagents Applications, Inc.
San Diego, California

Arthur Kessner, Ph.D.
Beckman Instruments, Inc.
Brea, California

Jacob B. Levine, M.B.A.
Bayer Corporation
Tarrytown, New York

W. Gregory Miller, Ph.D.
Virginia Commonwealth University
Richmond, Virginia

Nader Rifai, Ph.D.
Children’s Hospital
Boston, Massachusetts

Richard C. San George, Ph.D.
Waltham, Massachusetts

Michael J. Welch, Ph.D.
National Institute of Standards and Technology
Gaithersburg, Maryland

Donald A.Wiebe, Ph.D.
University of Wisconsin
Madison, Wisconsin

Advisors

Dennis Bozimowski, Ph.D.
Abbott Laboratories
Abbott Park, Illinois

Eileen Carreiro-Lewandowski
Pawtucket, Rhode Island

Jennifer Colbert
National Institute of Standards and Technology
Gaithersburg, Maryland
Advisors (Continued)

Irene M. Daza
Pennsylvania Department of Health
Lionville, Pennsylvania

Robert A. Dean
Indiana University Medical Center
Indianapolis, Indiana

Marvin C. Feil, F.A.I.C.
Corning Clinical Laboratories
Teterboro, New Jersey

Russell T. Joseph, M.S.
Paramax Chemistry
Irvine, California

Norbert Mantor, Ph.D.
St. Thomas Department of Health
St. Thomas, Virgin Islands

Alfred E. Peacock, Jr.
Reagents Applications, Inc.
San Diego, California

Robert Rej, Ph.D.
New York State Department of Health
Albany, New York

Cornelia B. Rooks, M.A.
FDA Center for Devices/Radiological Health
Rockville, Maryland

Michael Santulli, M.S.
Bayer Corporation
Tarrytown, New York

G. Russell Warnick, M.S., MBA
Pacific Biometrics, Inc.
Seattle, Washington

Robert E. Wenk, M.D.
Sinai Hospital of Baltimore
Baltimore, Maryland

Wei-Guo Zhao, M.D., M.S.
Dade Behring, Inc.
Newark, Delaware

Beth Ann Wise, M.T.(ASCP), M.S.Ed.
NCCLS
Wayne, Pennsylvania

Patrice E. Polgar
NCCLS
Wayne, Pennsylvania

Donna M. Wilhelm
NCCLS
Wayne, Pennsylvania

Staff Liaison

Editor

Assistant Editor
ACTIVE MEMBERSHIP (as of 1 October 1999)

Sustaining Members
Abbott Laboratories
American Association for Clinical Chemistry
Bayer Corporation
Beckman Coulter, Inc.
Becton Dickinson and Company bioMérieux, Inc.
College of American Pathologists
Dade Behring Inc.
Nippon Becton Dickinson Co., Ltd.
Ortho-Clinical Diagnostics, Inc.
Pfizer Inc
Roche Diagnostics, Inc.

Professional Members
American Academy of Family Physicians
American Association of Bioanalysts
American Association of Blood Banks
American Association for Clinical Chemistry
American Association for Respiratory Care
American Chemical Society
American Medical Technologists
American Public Health Association
American Society for Clinical Laboratory Science
American Society of Hematology
American Society for Microbiology
American Society of Parasitologists, Inc.
American Type Culture Collection, Inc.
Asociación Española Primera de Socorros (Uruguay)
Asociacion Mexicana de Bioquimica Clinica A.C.
Asn. of Public Health Laboratories
Australasian Association of Clinical Biochemists
British Society for Antimicrobial Chemotherapy
Canadian Society for Medical Laboratory Science—Société Canadienne de Science de Laboratoire Médical
Canadian Society of Clinical Chemists
Clinical Laboratory Management Association
College of American Pathologists
College of Medical Laboratory Technologists of Ontario
College of Physicians and Surgeons of Saskatchewan
Commission on Office Laboratory Accreditation
Danish Society of Clinical Chemistry
Fundacion Bioquimica de la Provincia (Argentina)
International Association of Medical Laboratory Technologists
International Council for Standardization in Haematology
International Federation of Clinical Chemistry
International Society for Analytical Cytology
Italian Society of Clinical Biochemistry
Japan Society of Clinical Chemistry
Japanese Committee for Clinical Laboratory Standards
Joint Commission on Accreditation of Healthcare Organizations
National Academy of Clinical Biochemistry
National Society for Histotechnology, Inc.
Ontario Medical Association Laboratory Proficiency Testing Program
Ordre professionnel des technologistes médicaux du Québec
RCPA Quality Assurance Programs PTY Limited
Sociedade Brasileira de Analises Clinicas
Sociedade Brasileira de Patologia Clinica
Sociedad Espanola de Quimica Clinica
VKCN (The Netherlands)

Government Members
Armed Forces Institute of Pathology
Association of Public Health Laboratory Directors
BC Centre for Disease Control
Centers for Disease Control and Prevention
Chinese Committee for Clinical Laboratory Standards
Commonwealth of Pennsylvania Bureau of Laboratories
Department of Veterans Affairs
Deutsches Institut für Normung (DIN)
FDA Center for Devices and Radiological Health
FDA Division of Anti-Infective Drug Products
Health Care Financing Administration/CLIA Program
Health Care Financing Administration
Iowa State Hygienic Laboratory
Massachusetts Department of Public Health Laboratories
Michigan Department of Public Health
National Association of Testing Authorities - Australia
National Center of Infectious and Parasitic Diseases (Bulgaria)
National Institute of Standards and Technology
Ohio Department of Health
Oklahoma State Department of Health
Ontario Ministry of Health
Saskatchewan Health-Provincial Laboratory
Scientific Institute of Public Health; Belgium Ministry of Social Affairs, Public Health and the Environment
South African Institute for Medical Research
Swedish Institute for Infectious Disease Control
Thailand Department of Medical Sciences

Industry Members
AB Biodisk
Abbott Laboratories
Accumetrics, Inc.
Amersham Pharmacia Biotech
Amiriri Regulatory Consulting Asséssor
AstraZeneca
Avocet Medical, Inc.
Bayer Corporation - Elkhart, IN
Bayer Corporation - Middletown, VA
Bayer Corporation - Tarrytown, NY
Bayer Corporation - West Haven, CT
Bayer Medical Ltd.
Beckman Coulter, Inc.
Beckman Coulter, Inc. Primary Care Diagnostics
Beckman Coulter K.K. (Japan)
Becton Dickinson and Company
Becton Dickinson Biosciences
Becton Dickinson Consumer Products
Becton Dickinson Immunocytometry Systems
Becton Dickinson Italia S.P.A.
Beckman Coulter, Inc. Primary Products
Becton Dickinson Consumer Products

International Technidyne Corporation
Johnson City Medical Center
Kendall Sherwood-Davis & Geck Labtest Diagnostica S.A.
LifeScan, Inc. (a Johnson & Johnson Company)
Lilly Research Laboratories
Medical Device Consultants, Inc.
Medical Laboratory Automation Inc.
MediSense Products (Div. Of Abbott Laboratories)
Medtronic Perfusion Systems
Merck & Company, Inc.
mvi Sciences (MA)
Nabi
Neometrics Inc.
Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.)
Nissui Pharmaceutical Co., Ltd.
Nippon Becton Dickinson Co., Ltd.
Norfolk Associates, Inc.
OBC Associates
Olympus Corporation
Optical Sensors, Inc.
Organon Teknika Corporation
Ortho-Clinical Diagnostics, Inc. (England)
Ortho-Clinical Diagnostics, Inc. (Raritan, NJ)
Ortho-Clinical Diagnostics, Inc. (Rochester, NY)
Oxoid Inc.
Pfizer Inc
Pharmacia & Upjohn
Procter & Gamble Pharmaceuticals, Inc.
The Product Development Group
Quest Diagnostics Incorporated
Quintiles, Inc.
Radiometer America, Inc.
Radiometer Medical A/S
David G. Rhoads Associates, Inc.
Rhône-Poulenc Rorer
Roche Diagnostics GmbH
Roche Diagnostics, Inc.
Roche Diagnostic Systems (Div. Hoffmann-La Roche Inc.)
Roche Laboratories (Div. Hoffmann-La Roche Inc.)
The R.W. Johnson Pharmaceutical Research Institute
Sanofi Diagnostics Pasteur
Sarstedt, Inc.
SARL Laboratoire Carron (France)
Schering Corporation

Schleicher & Schuell, Inc.
Second Opinion
SenDx Medical, Inc.
Showa Yakuhin Kako Company, Ltd.
SmithKline Beecham, S.A.
Streck Laboratories, Inc.
Sysmex Corporation (Japan)
Sysmex Corporation (Long Grove, IL)
The Toledo Hospital (OH)
Trek Diagnostic Systems, Inc.
Vetoquinol S.A.
Vysis, Inc.
Wallac Oy
Warner-Lambert Company
Wyeth-Ayerst
Xyletech Systems, Inc.
YD Consultant

Trade Associations
Association of Medical Diagnostic Manufacturers
Health Industry Manufacturers Association
Japan Association Clinical Reagents Ind. (Tokyo, Japan)
Medical Industry Association of Australia

Associate Active Members
67th CSH Wuerzburg, GE (NY)
121st General Hospital (CA)
Acadiana Medical Laboratories, LTD (LA)
Advocate Laboratories (IL)
Allegheny General Hospital (PA)
Allegheny University of the Health Sciences (PA)
Allina Laboratories (MN)
Alton Ochsner Medical Foundation (LA)
American Medical Laboratories (VA)
Anzac House (Australia)
Associated Regional & University Pathologists (UT)
Aurora Consolidated Laboratories (WI)
Baptist St. Anthony’s Health Network (TX)
Baystate Medical Center (MA)
Brazil De Promocao (Brazil)
Bristol Regional Medical Center (TN)
Brookdale Hospital Medical Center (NY)
Brooke Army Medical Center (TX)
Brooks Air Force Base (TX)
Broward General Medical Center (FL)
<table>
<thead>
<tr>
<th>Hospital Name</th>
<th>City, State/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calgary Laboratory Services</td>
<td>Calgary, AB, Canada</td>
</tr>
<tr>
<td>Cardinal Glennon Children's Hospital</td>
<td>MO</td>
</tr>
<tr>
<td>Central Kansas Medical Center</td>
<td>NY</td>
</tr>
<tr>
<td>Champlain Valley Physicians Hospital</td>
<td>(LA)</td>
</tr>
<tr>
<td>Children's Hospital</td>
<td>(LA)</td>
</tr>
<tr>
<td>Children's Hospital Medical Center</td>
<td>Akron, OH</td>
</tr>
<tr>
<td>Clendo Lab (Puerto Rico)</td>
<td></td>
</tr>
<tr>
<td>CLSI Laboratories (PA)</td>
<td></td>
</tr>
<tr>
<td>Colorado Mental Health Institute at Pueblo</td>
<td></td>
</tr>
<tr>
<td>Commonwealth of Kentucky CompuNet Clinical Laboratories (OH)</td>
<td></td>
</tr>
<tr>
<td>Consolidated Laboratory Services (CA)</td>
<td></td>
</tr>
<tr>
<td>Danville Regional Medical Center (VA)</td>
<td></td>
</tr>
<tr>
<td>Dean Medical Center (WI)</td>
<td></td>
</tr>
<tr>
<td>Detroit Health Department (MI)</td>
<td></td>
</tr>
<tr>
<td>Diagnostic Laboratory Services, Inc. (HI)</td>
<td></td>
</tr>
<tr>
<td>Duke University Medical Center (NC)</td>
<td></td>
</tr>
<tr>
<td>Durham Regional Hospital (NC)</td>
<td></td>
</tr>
<tr>
<td>Duzen Laboratories (Turkey)</td>
<td></td>
</tr>
<tr>
<td>Dynacare Laboratories - Eastern Region (Ottawa, ON, Canada)</td>
<td></td>
</tr>
<tr>
<td>E.A. Conway Medical Center (LA)</td>
<td></td>
</tr>
<tr>
<td>Elmhurst Memorial Hospital (IL)</td>
<td></td>
</tr>
<tr>
<td>Elyria Memorial Hospital (OH)</td>
<td></td>
</tr>
<tr>
<td>Emory University Hospital (GA)</td>
<td></td>
</tr>
<tr>
<td>Fairfax Hospital (VA)</td>
<td></td>
</tr>
<tr>
<td>Fairview-University Medical Center (MN)</td>
<td></td>
</tr>
<tr>
<td>Foothills Hospital (Calgary, AB, Canada)</td>
<td></td>
</tr>
<tr>
<td>Fox Chase Cancer Center (PA)</td>
<td></td>
</tr>
<tr>
<td>Franklin Square Hospital Center (MD)</td>
<td></td>
</tr>
<tr>
<td>Fresenius Medical Care/Life Chem (NJ)</td>
<td></td>
</tr>
<tr>
<td>Fresno Community Hospital and Medical Center</td>
<td></td>
</tr>
<tr>
<td>GDS Technology, Inc (IN)</td>
<td></td>
</tr>
<tr>
<td>Grady Memorial Hospital (GA)</td>
<td></td>
</tr>
<tr>
<td>Greater Southeast Community Hospital (DC)</td>
<td></td>
</tr>
<tr>
<td>Guthrie Clinic Laboratories (PA)</td>
<td></td>
</tr>
<tr>
<td>Halifax Medical Center (FL)</td>
<td></td>
</tr>
<tr>
<td>Harris Methodist Fort Worth (TX)</td>
<td></td>
</tr>
<tr>
<td>Harris Methodist Northwest (TX)</td>
<td></td>
</tr>
<tr>
<td>Hartford Hospital (CT)</td>
<td></td>
</tr>
<tr>
<td>Hays Pathology Laboratories, P.A. (KS)</td>
<td></td>
</tr>
<tr>
<td>Headwaters Health Authority (High River, AB, Canada)</td>
<td></td>
</tr>
<tr>
<td>Health Alliance Laboratory (OH)</td>
<td></td>
</tr>
<tr>
<td>Health Network Lab (PA)</td>
<td></td>
</tr>
<tr>
<td>Health Sciences Centre (Winnipeg, MB, Canada)</td>
<td></td>
</tr>
<tr>
<td>Heartland Health System (MO)</td>
<td></td>
</tr>
<tr>
<td>Hinsdale Hospital (IL)</td>
<td></td>
</tr>
<tr>
<td>Hoag Memorial Hospital Presbyterian (CA)</td>
<td></td>
</tr>
<tr>
<td>Holmes Regional Medical Center (FL)</td>
<td></td>
</tr>
<tr>
<td>Holy Spirit Hospital (PA)</td>
<td></td>
</tr>
<tr>
<td>Holzer Medical Center (OH)</td>
<td></td>
</tr>
<tr>
<td>Hospital for Sick Children (Toronto, ON, Canada)</td>
<td></td>
</tr>
<tr>
<td>Hospital Israelita Albert Einstein (Brazil)</td>
<td></td>
</tr>
<tr>
<td>Hotel Dieu Hospital (Windsor, ON, Canada)</td>
<td></td>
</tr>
<tr>
<td>Huddinge University Hospital (Sweden)</td>
<td></td>
</tr>
<tr>
<td>Hurley Medical Center (MI)</td>
<td></td>
</tr>
<tr>
<td>Indiana University Instituto Scientifico HS. Raffaele (Italy)</td>
<td></td>
</tr>
<tr>
<td>International Health Management Associates, Inc. (IL)</td>
<td></td>
</tr>
<tr>
<td>Intermountain Health Care Laboratory Services (UT)</td>
<td></td>
</tr>
<tr>
<td>Jacobi Medical Center (NY)</td>
<td></td>
</tr>
<tr>
<td>John Peter Smith Hospital (TX)</td>
<td></td>
</tr>
<tr>
<td>John Randolph Hospital (VA)</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins Medical Institutions (MD)</td>
<td></td>
</tr>
<tr>
<td>Johnson City Medical Center (IN)</td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente (CA)</td>
<td></td>
</tr>
<tr>
<td>Kenora-Rainy River Regional Laboratory Program (Dryden, Ontario, Canada)</td>
<td></td>
</tr>
<tr>
<td>Klinicni Center (Slovenia)</td>
<td></td>
</tr>
<tr>
<td>LabCorp (NC)</td>
<td></td>
</tr>
<tr>
<td>Laboratoire de Santé Publique du Quebec (Canada)</td>
<td></td>
</tr>
<tr>
<td>Laboratório Fleury S/C Ltda. (Brazil)</td>
<td></td>
</tr>
<tr>
<td>Laboratory Corporation of America (MO)</td>
<td></td>
</tr>
<tr>
<td>Lancaster General Hospital (PA)</td>
<td></td>
</tr>
<tr>
<td>Langley Air Force Base (VA)</td>
<td></td>
</tr>
<tr>
<td>Lewis-Gale Medical Center (VA)</td>
<td></td>
</tr>
<tr>
<td>Libero Instituto Univ. Campus BioMedico (Italy)</td>
<td></td>
</tr>
<tr>
<td>LAC and USC Healthcare Network (CA)</td>
<td></td>
</tr>
<tr>
<td>Louisiana State University Medical Center</td>
<td></td>
</tr>
<tr>
<td>Lutheran Hospital (WI)</td>
<td></td>
</tr>
<tr>
<td>Main Line Clinical Laboratories, Inc. (PA)</td>
<td></td>
</tr>
<tr>
<td>Massachusetts General Hospital</td>
<td></td>
</tr>
<tr>
<td>Mayo Clinic Scottsdale (AZ)</td>
<td></td>
</tr>
<tr>
<td>MDS Metro Laboratory Services (Burnaby, BC, Canada)</td>
<td></td>
</tr>
<tr>
<td>MDS-Sciex (Concord, ON, Canada)</td>
<td></td>
</tr>
<tr>
<td>Medical College of Virginia Hospital</td>
<td></td>
</tr>
<tr>
<td>Melrose-Wakefield Hospital (MA)</td>
<td></td>
</tr>
<tr>
<td>Memorial Hospital (CO)</td>
<td></td>
</tr>
<tr>
<td>Memorial Medical Center (N. Jefferson Davis Pkwy., New Orleans, LA)</td>
<td></td>
</tr>
<tr>
<td>Memorial Medical Center (IL)</td>
<td></td>
</tr>
<tr>
<td>Mercy Health System (PA)</td>
<td></td>
</tr>
<tr>
<td>Mercy Hospital (NC)</td>
<td></td>
</tr>
<tr>
<td>Methodist Hospital (TX)</td>
<td></td>
</tr>
<tr>
<td>Methodist Hospital Indiana</td>
<td></td>
</tr>
<tr>
<td>Methodist Hospitals of Memphis (TN)</td>
<td></td>
</tr>
<tr>
<td>Mid Michigan Medical Center - Midland</td>
<td></td>
</tr>
<tr>
<td>Milton S. Hershey Medical Center (PA)</td>
<td></td>
</tr>
<tr>
<td>Montreal Children's Hospital (Canada)</td>
<td></td>
</tr>
<tr>
<td>Montreal General Hospital (Canada)</td>
<td></td>
</tr>
<tr>
<td>Mount Sinai Hospital (NY)</td>
<td></td>
</tr>
<tr>
<td>National University Hospital (Singapore)</td>
<td></td>
</tr>
<tr>
<td>Naval Surface Warfare Center (IN)</td>
<td></td>
</tr>
<tr>
<td>Nebraska Health System</td>
<td></td>
</tr>
<tr>
<td>New Britain General Hospital (CT)</td>
<td></td>
</tr>
<tr>
<td>New England Medical Center Hospital (MA)</td>
<td></td>
</tr>
<tr>
<td>The New York Blood Center</td>
<td></td>
</tr>
<tr>
<td>The New York Hospital Medical Center of Queens</td>
<td></td>
</tr>
<tr>
<td>New York State Department of Health</td>
<td></td>
</tr>
<tr>
<td>NorDx (ME)</td>
<td></td>
</tr>
<tr>
<td>North Carolina Laboratory of Public Health</td>
<td></td>
</tr>
<tr>
<td>North Coast Clinical Laboratory, Inc. (OH)</td>
<td></td>
</tr>
<tr>
<td>Northridge Hospital Medical Center (CA)</td>
<td></td>
</tr>
<tr>
<td>Northwestern Memorial Hospital (IL)</td>
<td></td>
</tr>
<tr>
<td>Ohio State University Hospitals</td>
<td></td>
</tr>
<tr>
<td>Olin E. Teague Medical Center (TX)</td>
<td></td>
</tr>
<tr>
<td>Our Lady of Lourdes Hospital (NJ)</td>
<td></td>
</tr>
<tr>
<td>Our Lady of the Resurrection Medical Center (IL)</td>
<td></td>
</tr>
<tr>
<td>Pathology and Cytology Laboratories, Inc. (KY)</td>
<td></td>
</tr>
<tr>
<td>Permanente Medical Group (CA)</td>
<td></td>
</tr>
</tbody>
</table>
Presbyterian Hospital of Dallas (TX)
Providence Health System (OR)
Providence Medical Center (WA)
Queen Elizabeth Hospital (Prince Edward Island, Canada)
Queensland Health Pathology Services (Australia)
Quintiles Laboratories, Ltd. (GA)
Regions Hospital
Research Medical Center (MO)
Riyadh Armed Forces Hospital (Saudi Arabia)
Robert F. Kennedy Medical Center (CA)
Royal Columbian Hospital (New Westminster, BC, Canada)
Saint Mary's Regional Medical Center (NV)
St. Alexius Medical Center (ND)
St. Anthony Hospital (CO)
St. Boniface General Hospital (Winnipeg, Canada)
St. Elizabeth Hospital (NJ)
St. Francis Medical Center (CA)
St. John Hospital and Medical Center (MI)
St. John Regional Hospital (St. John, NB, Canada)
St. Joseph Hospital (NE)
St. Joseph Mercy – Oakland (MI)
St. Joseph's Hospital - Marshfield Clinic (WI)
St. Luke's Hospital (PA)
St. Luke's Regional Medical Center (IA)
St. Mary Hospital (NJ)
St. Mary Medical Center (CA)
St. Mary Medical Center (IN)
St. Mary of the Plains Hospital (TX)
San Francisco General Hospital (CA)
Santa Cabrini Hospital (Montreal, PQ, Canada)
Santa Clara Valley Medical Center (CA)
Seoul Nat'l University Hospital (Korea)
Shanghai Center for the Clinical Laboratory (China)
Shands Healthcare (FL)
SmithKline Beecham Clinical Laboratories (GA)
SmithKline Beecham Clinical Laboratories (WA)
South Bend Medical Foundation (IN)
Southern California Permanente Medical Group
South Western Area Pathology Service (Australia)
Speciality Laboratories, Inc. (CA)
Stanford Health Services (CA)
Stormont-Vail Regional Medical Center (KS)
Sun Health-Boswell Hospital (AZ)
Sunrise Hospital and Medical Center (NV)
Sutter Health (CA)
Tampa General Hospital (FL)
Timmons & District Hospital (Timmons, ON, Canada)
Tripler Army Medical Center (HI)
Trumbull Memorial Hospital (OH)
Tulane Medical Center Hospital & Clinic (LA)
Twin Lake Regional Medical Center
UCSF Medical Center (CA)
UNC Hospitals (NC)
Unilab Clinical Laboratories (CA)
University of Alabama - Birmingham Hospital
University of Alberta Hospitals (Canada)
University of Chicago Hospitals (IL)
University Hospital (IN)
University Hospital (Gent) (Belgium)
University Hospital (London, Ontario, Canada)
The University Hospitals (OK)
University of Massachusetts Lowell
University of Medicine & Dentistry, NJ University Hospital
University of Michigan
University of the Ryukyus (Japan)
University of Texas Medical School at Houston
University of Virginia Medical Center
University of Washington
UPMC Bedford Memorial (PA)
USAF Medical Center (OH)
UZ-KUL Medical Center (Belgium)
VA (Dayton) Medical Center (OH)
VA (Denver) Medical Center (CO)
VA Outpatient Clinic (OH)
VA (San Diego) Medical Center (CA)
VA (Tuskegee) Medical Center (AL)
Vejle Hospital (Denmark)
Viridae Clinical Sciences, Inc. (Vancouver, BC, Canada)
ViroLogic, Inc. (CA)
Waikato Hospital (New Zealand)
Walter Reed Army Institute of Research (MD)
Warde Medical Laboratory (MI)
Warren Hospital (NJ)
Washoe Medical Center (NV)
Watson Clinic (FL)
Wilford Hall Medical Center (TX)
William Beaumont Hospital (MI)
Williamsburg Community Hospital (VA)
Wilson Memorial Hospital (NY)
Winchester Hospital (MA)
Winn Army Community Hospital (GA)
Wisshard Memorial Hospital (IN)
Womack Army Medical Center (NC)
Yonsei University College of Medicine (Korea)
York Hospital (PA)
Zale Lipshy University Hospital (TX)
### OFFICERS

- William F. Koch, Ph.D., President
  National Institute of Standards and Technology
- F. Alan Andersen, Ph.D., President Elect
  Cosmetic Ingredient Review
- Robert F. Moran, Ph.D., FCCM, FAIC
  Secretary
  mvi Sciences
- Donna M. Meyer, Ph.D., Treasurer
  CHRISTUS Health
- A. Samuel Koenig, Ill, M.D., Past President
  Family Medical Care
- John V. Bergen, Ph.D., Executive Director

### BOARD OF DIRECTORS

- Sharon S. Ehrmeyer, Ph.D.
  University of Wisconsin
- Robert L. Habig, Ph.D.
  Cytometrics, Inc.
- Thomas L. Hearn, Ph.D.
  Centers for Disease Control and Prevention
- Gerald A. Hoeltge, M.D.
  The Cleveland Clinic Foundation
- Elizabeth D. Jacobson, Ph.D.
  FDA Center for Devices and Radiological Health
- Carolyn D. Jones, J.D., M.P.H.
  Health Industry Manufacturers Association
- Hartmut Jung, Ph.D.
  Roche Diagnostics GmbH
- Tadashi Kawai, M.D., Ph.D.
  International Clinical Pathology Center
- Barbara G. Painter, Ph.D.
  Bayer Corporation
- Marianne C. Watters, M.T.(ASCP)
  Parkland Health & Hospital System
- Ann M. Willey, Ph.D.
  New York State Department of Health
- Judith A. Yost, M.A., M.T.(ASCP)
  Health Care Financing Administration
Contents

Abstract.............................................................................................................................................. i

Committee Membership....................................................................................................................... v

Active Membership................................................................................................................................ vii

Foreword................................................................................................................................................ xv

1 Introduction......................................................................................................................................... 1

2 Scope.................................................................................................................................................. 1

3 Standard Precautions....................................................................................................................... 1

4 Definitions .......................................................................................................................................... 1

5 Design Considerations .................................................................................................................... 2

  5.1 Pool Preparation.......................................................................................................................... 2

  5.2 Validation of Performance and Commutability ............................................................................ 4

6 Raw Materials..................................................................................................................................... 5

  6.1 Donor Selection............................................................................................................................ 5

  6.2 General Exclusion Criteria for Donor Units and Pools ............................................................... 5

7 Blood Collection and Processing Procedure .................................................................................... 5

References ............................................................................................................................................... 7

Appendix A. Quality Control Sampling Test for Pool Homogeneity ...................................................... 9

  A1 Test Objective ............................................................................................................................. 9

  A2 Test Assumptions ........................................................................................................................ 9

  A3 Test Plan ..................................................................................................................................... 9

  A4 Data Analysis ............................................................................................................................. 9

Appendix B. Verification of Material Specifications ............................................................................... 10

  B1 Validation Study Materials ......................................................................................................... 10

  B2 Donor Selection .......................................................................................................................... 10

  B3 Materials and Apparatus ............................................................................................................ 12

  B4 Blood Collection and Processing .............................................................................................. 13

  B5 Testing Procedures Relevant to Production of Cholesterol Pools .............................................. 14

  B6 Materials Validation Results ....................................................................................................... 15

  B7 Certificates of Analysis for Cholesterol Pools .......................................................................... 17

Summary of Comments and Subcommittee Responses ......................................................................... 21

Related NCCLS Publications .............................................................................................................. 26
Foreword

Numerous epidemiological and clinical investigations across the world have documented that elevated levels of blood cholesterol are a major risk factor for coronary heart disease (CHD) and that lowering blood cholesterol levels decreases morbidity and mortality from CHD. Reduction in the prevalence of elevated blood cholesterol has been a primary objective of the National Cholesterol Education Program (NCEP), established in 1985 by the National Heart, Lung and Blood Institute. The efforts of NCEP and other similar international cholesterol education programs to reduce high blood cholesterol are based on the need for reliable blood cholesterol measurements for proper patient risk classification. An important milestone in the NCEP effort was the establishment of the National Reference System for Cholesterol (NRS/CHOL) by NCCLS, which provides the accuracy target for cholesterol measurement. The NCEP’s Laboratory Standardization Panel recommended that all cholesterol measurements be standardized and traceable to the NRS/CHOL. It is extremely important that manufacturers of clinical instruments, reagents, and calibrator materials, as well as clinical laboratories, have available to them reference materials that will establish traceability to the NRS/CHOL and assure true and precise results on human subjects, in all field methods being used worldwide. In order to achieve this goal, reference materials with long-term stability and appropriate analyte concentrations are required.

An additional very important requirement is commutability, termed “transmutability” by some investigators. Even though often prepared from human sources, processed reference materials in the past have often taken on properties, loosely termed “matrix effects,” that make them behave differently from patient specimens in some reagent/instrument systems. Matrix effects differ from more typical analytical interferences in that the latter are effects of exogenous (e.g., drug) or endogenous (e.g., bilirubin) substances that have similar effects on both patient and manufactured control and calibrator materials. In contrast, matrix effects are properties that are unique to the processed reference materials (and control materials). Since matrix effects lead to underrecovery, or less commonly overrecovery, of the analyte of interest in some field methods, knowing very true and precise analyte concentrations on a reference material which demonstrates matrix effects with certain field methods does little to transfer trueness to those methods.

The currently accepted approach to document traceability to the NRS/CHOL for many field methods is via a split-sample comparison with the reference method using fresh human serum specimens. The presence or absence of matrix-effect interferences with field methods in a given sample can be confirmed by direct comparison of field method measurements with measurements from a reference method which is not subject to matrix effects. Protocols have been developed which can identify matrix effects in particular materials. However, the use of commutable reference materials is the preferred approach and, therefore, a need exists to develop reference materials for cholesterol measurement procedures that do not demonstrate matrix effects. The few materials-formulation guidelines that exist are of a generic nature, not specifically addressing the problem of modern cholesterol methods and the newer, high-throughput, microsampling analytical equipment. It is therefore clear that there is a significant gap in the NRS/CHOL and that an immediate need exists for agreement on material standards applicable to the establishment of the calibration and trueness of serum cholesterol measurement systems.

Key Words

Cholesterol, commutable, matrix effects, NRS/CHOL, reference materials, serum pools, traceability
Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline

1 Introduction

This guideline describes the procedures for preparing frozen human serum pools of high quality suitable for cholesterol measurement. Although prepared for cholesterol, the concepts described in this written guideline may be applied to the preparation of frozen human serum pools for other analytes.

2 Scope

These specifications are designed to enable laboratory scientists, in vitro diagnostic (IVD) manufacturers, proficiency testing providers, and suppliers of clinical laboratory reference materials to prepare frozen human serum pools which demonstrate minimal matrix effects, are commutable across different cholesterol measurement procedures, and, as such, are suitable for assessing the trueness of these procedures. These serum pools, when assigned target values by the definitive method and/or reference method of the National Reference System for Cholesterol (NRS/CHOL), may be used to properly calibrate and/or assess trueness of field methods for serum cholesterol measurement, and provide an alternative method to split-sample comparisons with human specimens for establishing traceability of calibration of field methods to the NRS/CHOL. This document provides guidance for collecting and processing raw materials to manufacture frozen serum pools and for performing quality assurance of the final product. As part of the guideline development, two frozen human serum pools using a large number of selected individual donor units of "off-the-clot" serum were prepared and characterized. The performance of the pools was assessed in terms of the degree of commutability (observed response versus predicted response) relative to the individual sera which comprised the pools.

3 Standard Precautions

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to "standard precautions." Standard precautions are new guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of any pathogen and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Guideline for Isolation Precautions in Hospitals, Infection Control and Hospital Epidemiology, CDC, Vol 17;1:53-80.). [MMWR 1987;36(suppl 2S):2S-18S] and (MMWR 1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure, refer to NCCLS document M29—Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue.

4 Definitions

Accuracy, n - Closeness of the agreement between the result of a measurement and a true value of the measurand. NOTE: The concept of accuracy of measurement is described by trueness of measurement and precision of measurement. Thus, accuracy is not a synonym for trueness or for precision (VIM: 1993, 3.5[16]).

Aseptic, adj - Environmental conditions which minimize microbial contamination.

---

a Examples of suppliers of reference materials in the U.S are the National Institute of Standards and Technology, the College of American Pathologists, and the Centers for Disease Control and Prevention.

b Some of these definitions are found in NCCLS document NRSCLB—Terminology and Definitions for Use in NCCLS Documents. For complete definitions and detailed source information, please refer to the most current edition of that document.
**Commutable, adj** - Interassay properties of a reference material, calibrator material, or quality control material that are comparable with those demonstrated by authentic clinical specimens.

NOTE: Commutability of a material is defined as the “degree to which a material yields the same numerical relationships between results of measurements by a given set of measurement procedures, purporting to measure the same quantity, as those between the expectations of the relationships obtained when the same procedures are applied to other relevant types of material” (CEN prEN 12287:1999, 3.5).

**Hemolysis, n** - Serum appearing red or pink in color resulting from the breakdown of red blood cells liberating hemoglobin.

**Homogeneity, n** - The condition of being of uniform structure or composition with respect to one or more specified properties.

**Icterus, n** - Serum with yellow color resulting from elevated bilirubin in the blood.

**Lipemia, n** - A milky or turbid serum resulting from elevated lipids in the blood.

**Matrix effect, n** - The influence of a component in the sample, other than the analyte, on the measurement, and thereby on the value, of the measurable quantity.

**Off-the-clot serum, n** - The liquid remaining after neat whole blood has coagulated and the clot has retracted and/or been spun down in a centrifuge to separate the clot from the liquid portion.

**Reference material, n** - A material or substance, one or more of whose property values are sufficiently homogeneous and will be used for the calibration of an apparatus, the assessment of a measurement method, or for assigning values to materials (ISO Guide 30:1992, 2.1), (VIM: 1993, 6.13). NOTE: A given reference material may be used either as a calibration material in calibration of a measuring system and in assigning values to materials, or as a control material in assessing the performance of a measurement procedure, but must not be used for both purposes in a given situation in a particular laboratory.

**Traceability, n** - The property of the result of a measurement or the value of a standard whereby it can be related to stated references, usually national or international standards, through an unbroken chain of comparisons, all having stated uncertainties.

**Trueness, n** - Closeness of agreement between the average value obtained from a large series of results of measurements and a true value.

NOTES: a) Trueness of measurement cannot be given a numerical value, but can be expressed on an ordinal scale such as (low, medium, high); b) Trueness is usually expressed numerically by the statistical measure bias that is inversely related to trueness. (ISO 3534-1:1993), (ISO 5725-1:1994). See also Accuracy.

### 5 Design Considerations

#### 5.1 Pool Preparation

During the deliberations that took place to develop this guideline, a number of issues that could significantly impact the quality of the final product were considered. The most important of these issues are presented briefly here.

The collection conditions used for the individual units are designed to provide off-the-clot serum with minimal degradation or modification during handling and processing. Completion of blood collection and processing, dispensing, and freezing must be done as quickly as possible to assure the quality of the final product.

A major assumption made when preparing serum pools by combining donor units is that the behavior of the pooled sera is not adversely affected by the influence of any human sample-specific biases. The effect of an interference that might occur from a donor can be estimated by assuming that bias is proportional to the donor's serum volume contribution to the pool. If this assumption is correct, the bias introduced into the pool is the bias of the single-donor divided by the total number of donors (Bias_{pool} = Bias_{donor}/N). For example, if a single-donor sample had a large cholesterol bias of 30% due to interferences, a 1-% bias in a pool comprised of 30 donors would result. Therefore it is important to use a sufficient number of donors in order to minimize the effect any single donor might have on the pool.
Collection into plastic blood bags is recommended as an industry standard procedure. However, plastic blood collection bags are suspected of contaminating serum with phthalate esters and other plasticizer chemicals, depending on the length of contact time with the plastic. It is believed that serum left in contact with plastic blood collection bags for extended periods will alter the lipoproteins and thus adversely affect the biochemical stability of the pool. Collection with the blood bag in ice water prevents clotting to allow rapid separation of plasma from cells. Rapid separation of red blood cells from plasma prior to clotting minimizes exposure to cells and plastic to avoid biochemical processes and contamination from plastic-derived molecules. Centrifugation conditions for the cold blood bags were chosen to produce plasma with adequate platelets for clotting after aseptic transfer into glass bottles. Plasma is transferred to a sterile glass bottle for clotting to minimize the time exposed to plastic surfaces. Evacuated bottles should not be used to receive the plasma, because flow through the tubing must be controlled with a pinch valve to prevent frothing of the plasma which can introduce an undesirable random variable in the process.

The two pools prepared to validate this guideline were evaluated for the presence of plasticizer chemicals. The toxicology laboratory at the University of Wisconsin Hospital and Clinics (UWHC), Madison, Wisconsin, performed a qualitative assessment of these two serum pools by GC/MS to detect the presence of plasticizers. Two additional samples were included in the evaluation: one sample obtained from the UWHC Blood Bank (outdated unit of autologous frozen serum stored in plastic), and the second was drug-free serum prepared in-house from material collected and stored in glass. Cholesterol (free) was the predominant peak noted in each sample tested, along with a series of peaks for free fatty acids. It is of interest to note that the free fatty acids of the two pools prepared by these guidelines were minor compared to the free cholesterol suggesting minimal disruption of the lipid and lipoprotein characteristics of the original donors. A major peak that has the characteristics of phthalate esters typically found in plasticizers was detected in the blood bank specimen. This peak was of minor consequence in the two pools prepared according to this guideline. The impact of trace amounts of phthalate esters present in the materials was not evaluated as part of this project.

Aseptic handling wherever possible will minimize exposure to potential microbial contamination, and relatively short times at ambient temperature minimizes bacterial growth in the event of contamination. Glass containers used during the blood processing steps were sterilized by autoclaving to prevent bacterial contamination.

Borosilicate glass containers with Teflon®-lined caps and stoppers should be used for processing serum and for storage vials. These materials are selected to minimize contamination from surface interactions and chemical leaching.

Membranes for filtration of the serum pool should be selected to minimize adsorption of proteins or other serum constituents. The membranes should be tested for suitability by measuring critical analytes before and after a trial filtration. Polyvinylidene difluoride membranes meet these requirements. Membranes should be washed appropriately to avoid contamination with preservative materials.

Individual serum units are not filtered prior to pooling, in order to match as closely as possible the matrix usually used for testing in a clinical laboratory, and to avoid increased risk of bacterial contamination. Not filtering individual units also minimizes the time between collection of blood and freezing of the pooled sera.

It is desirable to avoid shipping serum units from a collection center to a pool preparation center. Shipping introduces a random variable into the process which has the potential for degradation of the serum. If shipping cannot be avoided, the serum containers must be 100% filled with no air space. This condition minimizes the opportunity for mechanical agitation and denaturation of protein and other constituents. Shipping conditions must be adequate to maintain temperature of all material at ≤8 °C.

Freezing of the pooled sera is critical. Freezing conditions should be uniform for each vial. A maximum temperature of -70 °C should be
achieved for storage of the frozen sera. This temperature is necessary for complete ice formation and immobilization of water molecules in the presence of the serum matrix constituents. Complete ice formation limits molecular diffusion and interactions which can result in degradation of lipoproteins and other molecules over time.

Following initial freezing, vials must be handled for transfer or shipping in such a way that they do not experience greater than one hour cumulative between -70 to -30 °C. Any vial in which the contents become partially or fully liquefied must be immediately used or discarded. Material should not be refrozen.

5.2 Validation of Performance and Commutability

Commutability of the prepared reference material must be demonstrated through an appropriate validation procedure. Commutability of a reference material is demonstrated when the reference material shows intermethod changes in response, per measurement unit, comparable to the changes observed for native individual human serum samples. Validation of the commutability of a reference material is therefore demonstrated when the reference material yields a consistent numerical or ratiometric relationship for the among-methods results, when compared to the among-methods numerical relationship (for the same measurement methods) established with the relevant routine test samples (i.e., freshly collected individual donor human serum.)

For the reference materials prepared to verify this written guideline, aliquots of the original individual donor serum units were retained and set aside before pooling for later use in the validation studies. An alternative approach which may be considered is use of an independent series or panel of selected individual human specimens, employing donor selection criteria as outlined in this written guideline. The advantage of the first approach (retained aliquots of the original donor units) is that it also permits an evaluation to rule out the effects of pooling on the performance of the reference materials. The results obtained with the pooled reference materials should be fully predictable from the mathematical summation and averaging of the results for the individual donors, if there is no significant pooling effect. The second approach (independent series or panel of specimens) may be preferred, since an interference imparted to the pool by a single donor is sometimes not linear after dilution with sera of other donors. Lack of predictability of interferences underscores the importance of performing commutability verification studies with each pool, as part of a routine quality assurance process, prerequisite to releasing a given pool for use as a reference material.

With either approach to validation, the protocol is essentially a series of method comparison studies, which includes the candidate reference materials, tested in parallel with the panel of individual human serum samples. Although a full panel of fresh human serum samples is preferred, it may not be practical to obtain the range of samples appropriate to cover the reportable range of the method/procedure in a time frame that would support such a study. In a situation where samples need to be preserved to support validation studies of performance and commutability, careful storage of the samples at –70 °C is required. Analysis of the data focuses on the establishment of the intermethod numerical relationships, determined separately for the individual donor samples and the candidate reference materials. To demonstrate commutability, the calculated ratios, or numerical relationships obtained for these separate comparisons (method-to-method for a panel of individual donor specimens), should be statistically equivalent.

For more detail on specific analytical methodology for the statistical comparisons required, the papers by Eckfeldt$^{12}$ and Long$^{22}$ should be consulted. Additional details of the validation studies for the reference materials described in this guideline are found in Appendix B.

6 Raw Materials

6.1 Donor Selection

Donors should be selected according to accepted criteria and local governmental regulations. $^c$ An informed consent must be

$^c$ For example, Technical Manual of the American Association of Blood Banks (AABB, Arlington, VA 22209).
obtained in writing from each donor after the specific collection procedure is explained and the donor is cautioned as to possible risks associated with blood donation. As part of the informed consent, donors should be informed of any tests performed on blood collected, the availability of results to donors, and the end use of blood collected. Adequate safeguards for donor privacy must be ensured. Donors should be prescreened and segregated according to desired concentration levels and number of pools required. They should fast for a minimum of eight hours prior to blood collection.

6.2 General Exclusion Criteria for Donor Units and Pools

Serum units and/or pools (as indicated) should be tested and accepted if the following specifications are met:

- Each unit—Should be negative for antibodies to human immunodeficiency virus, hepatitis B surface antigen, and antibody to hepatitis C virus.

- Each unit—For serum cholesterol and triglycerides, units outside of needed ranges should be rejected. “Spiking” to achieve cholesterol and triglyceride levels is specifically prohibited.

- Each unit and pool—Absence of clotting elements. To test for this, heat an aliquot of serum to 55 °C for five minutes. Turbidity measured at 710 nm in a 1-cm cuvette should remain constant after heating (±0.03 A).

- Each unit and pool—OD < 0.5 at 710 nm in a 1-cm cuvette.

- Each unit—Bilirubin < 1.5 mg/dL (25.6 μmol/L).

- Each unit—Total protein 5.8 to 8.0 g/dL (58 to 80 g/L).

- Each unit—Hemoglobin < 30 mg/dL (0.3 g/L).

- Each unit—Should be visually clear, straw-, or yellow-colored and free from particulate matter.

- Each unit and pool—pH = 7.4 to 8.2.

- Each unit and pool—Albumin/globulin ratio > 1.0.

- Each unit and pool—Glucose >60 mg/dL (3.33 mmol/L). “Spiking” to achieve glucose levels is specifically prohibited.

- Pool—Ammonia: Target to < 100 μmol/L. The pool should be rejected if ammonia exceeds 150 μmol/L.

- Pool—Microbial contaminates: Standard agar cultures must yield growth of < 10 CFUs per mL of pooled serum.

- Pool—Additional microbial testing must be performed to specifically rule out the presence of the following pathogenic organisms: *Escherichia coli*, *Salmonella*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*.

- Pool—Homogeneity. Test the final pool(s) to assess uniformity of all vials relative to cholesterol concentration, per Appendix A.

7 Blood Collection and Processing Procedure

Refer to Appendix B3.1 for details on materials and apparatus suitable for use with the written guideline. Items can be used which are equivalent to those used in procedures reported here.

1. Collect, in an ice-water bath, individual donor units of whole blood using an industry-standard empty blood-pack with integral donor tube, a 15-gauge needle, and a 600-mL plastic container.

2. Within five minutes of unit collection, before unit clots, separate plasma from cells by centrifugation at 1,500 x g for eight minutes at 4 °C.

3. Aseptically express plasma into a clean and sterile 250-mL borosilicate glass bottle with a Teflon®-lined screw cap. Avoid using vacuum bottles. Control plasma flow into the transfer bottle to avoid spattering and frothing.

4. Allow clotting to proceed at room temperature until clot retracts fully from
the serum. To maximize collection yield, clotting time should be three to four hours.

(5) Centrifuge each unit at 2,700 x g for at least 19 minutes.

(6) Aseptically transfer clear serum layer to a clean and sterile 250-mL borosilicate glass bottle with Teflon®-lined screw cap. Test for absence of clotting elements (per Section 6.2, third bullet). If negative, proceed with Step 7. If positive, repeat Steps 4 to 6, one additional cycle. If positive result persists, reject unit.

(7) Exclude lipemic, icteric, or hemolyzed serum units. Perform tests for attributes (see Section 6.2). Units failing any of these tests should be rejected from the pool.

(8) Store all units at 4 °C, and maintain chilled until pooling. Do not freeze. If transportation is required at this stage, the method should avoid agitation of the liquid.

(9) Prior to pooling (after storage at 4 °C), visually inspect each unit to assure that it is clear, straw- or yellow-colored liquid, free of particulates.

(10) Prepare the serum pool using the serum from the donor units (units selected for inclusion in a pool based on specific analyte level desired).

(11) Let pool incubate at 4 °C for 18 hours with constant, low-speed, magnetic stirrer mixing to assure homogeneity of the final pool and to allow any interactions to occur between molecules from individual units.

(12) Sterile filter pool through a 0.22 μm absolute filter (hydrophilic membrane). Collect filtrate into an appropriate sized sterile glass flask prior to final dispensing of pool (add sterile Teflon® stir bar).

(13) Aseptically transfer desired volume aliquots of pooled serum to final containers and stopper and seal. Maintain pool at 4 °C on ice with constant stirring to assure homogeneity of product throughout the dispensing process.

(14) Uniformly freeze the pool. Do not use Styrofoam racks or boxes which may cause freezing gradients from the outside to the inside of the container. All vials must be frozen in an upright position. Place all sample boxes in the freezer at the same time, being sure that each box is in direct contact with the metal shelf of the freezer.

(15) Store the filled containers at -70 °C.

(16) Blood collection, processing, dispensing, capping, crimping, freezing, and storage of the pool should be completed within 56 hours.
References


Appendix A. Quality Control Sampling Test for Pool Homogeneity

A1 Test Objective

Assure that serum pools prepared according to guideline demonstrate uniformity across the production lot for cholesterol concentration.

A2 Test Assumptions

Cholesterol homogeneity testing is to be conducted with a cholesterol method which has a within-run coefficient of variation of ≤ 1.5%. The vendor should confirm the within-run coefficient of variation for the method of choice.

A3 Test Plan

(1) Select one vial from each of a minimum of 15 different periods spaced in time equally throughout the dispensing/ aliquoting run.

(2) For each pool, perform in a single run, quadruplicate cholesterol analyses on each of the 15 sample vials. This design will allow an analysis of variance to be run to check for significant vial-to-vial variability within periods of the dispensing run and to check for significant vial-to-vial variability over the entire dispensing run.

A4 Data Analysis

(1) Analyze the data using a one-way analysis of variance (ANOVA). The analysis of variance table will appear as follows:

<table>
<thead>
<tr>
<th>Source of Variation</th>
<th>DF</th>
<th>Expected Mean Square</th>
</tr>
</thead>
<tbody>
<tr>
<td>Among vial</td>
<td>14</td>
<td>( (S_a)^2 + (4)(S_v)^2 ) (A)</td>
</tr>
<tr>
<td>With-in vial</td>
<td>45</td>
<td>( (S_a)^2 ) (B)</td>
</tr>
</tbody>
</table>

where \( (S_a)^2 \) is the analytic variance, \( (S_v)^2 \) is the vial-to-vial variance [i.e., the heterogeneity of the pool], and DF is the degrees of freedom associated with the mean square estimate. Four is the number of replicate determinations per vial.

(2) Calculate the F-ratio formed by \( \frac{\text{Mean Square A}}{\text{Mean Square B}} \) with 14 and 45 degrees of freedom. The critical value of F (probability = 0.05) for this comparison is 1.918. If the calculated F-ratio is greater than 1.918, the vial-to-vial variation for the pool may be too large and therefore the pool should be evaluated further to substantiate the homogeneity of the pool before considering rejection.

NOTE: This procedure provides a test of the null hypothesis that the vial-to-vial variance is zero (i.e., the pool is perfectly homogenous) versus the alternative hypothesis that the vial-to-vial variance is greater than zero (i.e., the pool is not perfectly homogeneous). The sample size (i.e., the number of vials and the number of measurements per vial) was chosen so that the F-test would have probability of 0.80 or greater of rejecting a pool with a vial-to-vial coefficient of variation ≥ 1%. In order for the F-test to have the stated power, it is very important that the within-run coefficient of variation be no larger than 1.5%.
Appendix B. Verification of Material Specifications

To validate the written guideline, the subcommittee had prepared, according to the material specifications, two frozen serum pools using a large number of selected individual donor units of "off-the-clot" serum. The performance of the pools was assessed in terms of the degree of commutability (true response versus predicted response) relative to the individual sera which comprise the pools. This section describes the preparation and evaluation of the donor units and pools (Figure B1) and the study conducted to validate the guideline.

B1 Validation Study Materials

Two pools of off-the-clot human serum (combined per cholesterol level within specified ranges) were prepared, packaged in 1-mL aliquots (each contained in a 3-mL glass vial), labeled, and frozen. Sixty 1-mL aliquots (each contained in a 3-mL glass vial), uniquely labeled and traceable to the original donor unit, were collected from each of the approximately 80 individual donor units (44 for Pool 1 and 43 for Pool 11).

B2 Donor Selection

B2.1 Criteria

Donors were selected according to selection criteria in the *Technical Manual of the American Association of Blood Banks*. Donors were prescreened for serum cholesterol concentration and divided into two groups.

Recommended analyte ranges for two cholesterol pools were: cholesterol 160 to 230 mg/dL (4.14 to 5.96 mmol/L) with triglycerides < 200 mg/dL (2.26 mmol/L); and cholesterol 240 to 380 mg/dL (6.22 to 9.84 mmol/L) with triglycerides < 300 mg/dL (3.39 mmol/L). Selected donors were asked to fast a minimum of eight hours.

Donors were recruited based on previous history of lipid values and their willingness to provide a fasting unit of whole blood. Donors with cholesterol concentrations of less than 200 mg/dL (5.18 mmol/L) and triglyceride concentration of less than 200 mg/dL (2.26 mmol/L) were scheduled for collection during the morning hours of two consecutive days for preparation of the low/normal-lipid pool. A week later individuals with lipids expected in the range of 260 to 350 mg/dL (6.73 to 9.06 mmol/L) cholesterol and triglycerides less than 300 mg/dL (3.39 mmol/L), were again scheduled for two consecutive days to prepare the high lipid pool. A minimum of 40 donors would be required for each pool preparation; however, 52 individuals were processed for the low/normal-lipid pool and an additional 58 donors were recruited for the higher pool to account for any individual units that might fail to meet the criteria.

---

COLLECT UNITS ON ICE FROM FASTING DONORS; COLLECT SAMPLE FOR BLOODTYPING, HIV, HEPATITIS TESTING

IMMEDIATELY CENTRIFUGE 1500 x g AT 4°C FOR 8 MIN.

TRANSFER PLASMA TO GLASS BOTTLE, TEFLOM LINED CAP, FOR CLOTTING 3-4 HOURS

CENTRIFUGE GLASS BOTTLE AT 4°C UNDER CONDITIONS TO COMPRESS CLOT

TRANSFER SERUM TO GLASS BOTTLES, TEFLOM LINED CAPS, TEFLOM STIR BARS IN BOTTLES. COMPLETE SETUP STERILE.

ASPIRATE SERUM ALIQUOT TO PERFORM ABSENCE OF CLOTTING ELEMENTS TEST 6.2 (3)

PERFORM TESTS FROM 6.2 (1) TO 6.2 (11)

STORE AT 4°C

INSPECT FOR COLOR, SEDIMENT, TURBIDITY

ALIQUOT 60 1-mL SAMPLES INTO 3mL GLASS VIALS

POOL 120-mL OF EACH UNIT (SORTED BY CHOL & TRIG LEVEL PER 8.2.3)

STERILE FILTER

ALIQUOT INTO 4800 3-mL GLASS VIALS

TEST ALIQUOTS ACCORDING TO 6.2 (3), (4), (9)-(15)

FREEZE INDIVIDUAL AND POOLED ALIQUOTS SIMULTANEOUSLY AND HOMOGENEOUSLY AT -70°C

Figure B1. Preparation and Evaluation of the Donor Units and Pools
B2.2 General Exclusion Criteria for Individual Units

- All HbsAg, HIV Ab, and HCV Ab positive serum units
- Serum units that failed routine clinical test criteria as follows:
  a. Total Protein 5.8 to 8.0 g/dL (58 to 80 g/L)
  b. Optical density < 0.5 at 710 nm
  c. Bilirubin < 1.5 mg/dL (25.6 μmol/L)
  d. Hemoglobin < 30 mg/dL (0.3 g/L)
  e. pH = 7.4 to 8.2
  f. A/G ratio > 1.0
  g. Glucose > 60 mg/dL (3.33 mmol/L)
  h. Absence of clotting factors
  i. Desired group lipid characteristics

B2.3 Cholesterol and Triglyceride Acceptance Criteria

<table>
<thead>
<tr>
<th>Pool</th>
<th>Cholesterol</th>
<th>Triglyceride</th>
<th>Appearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>180 to 200 mg/dL</td>
<td>&lt;200 mg/dL (4.66 to 5.18 mmol/L)</td>
<td>no turbidity</td>
</tr>
<tr>
<td>Group B</td>
<td>260 to 350 mg/dL</td>
<td>&lt;300 mg/dL (6.73 to 9.06 mmol/L)</td>
<td>no turbidity</td>
</tr>
<tr>
<td></td>
<td>(2.26 mmol/L)</td>
<td>(3.39 mmol/L)</td>
<td></td>
</tr>
</tbody>
</table>

B3 Materials and Apparatus

B3.1 Apparatus

- Whole blood collection kits with 600-mL capacity, Teruflex B-600 code BB, Terumo Corp., Tokyo, Japan.
- Refrigerated centrifuge equipped with six-place rotor TY-JS4.2 and six carriers (339127), Model Beckman J6B.
- Glass bottles (200 mL) with Teflon®-lined screw caps (210-25-010), VWR Scientific.
- Refrigerated centrifuge equipped with a four-place rotor H1008 and single-slot carriers (250), Model Sorvall RT6000, DuPont.
- Sterile filters with 0.22-μm hydrophilic membranes, KVGL 04HB3, Durapore® Millipore.
- Pressurized stainless steel tank with a 5-gal. (18.9-L) capacity (RG5), Amicon, Inc., Beverly, MA.
- Borosilicate, 250-mL capacity, serum bottles with Teflon®-lined screw caps (219817); 3-mL borosilicate clear "400" glass vials (223715); 13-mm gray Teflon®-coated stoppers (1012-4620); and center tear-out aluminum crimp seals (224182-01), Wheaton Science Products, Millville, NJ.
- Foot-controlled dispenser, Unispense (374301) and an air-powered crimper (224382), Wheaton Science Products, Millville, NJ.
- Hitachi 705 chemistry analyzer, Boehringer Mannheim Corporation, Indianapolis, IN.
- Model DU-20 spectrophotometer, Beckman Instruments, Fullerton, CA.
B3.2 Reagents

- Reagents for HbsAg, HIV Ab, and HCV Ab testing were purchased from Abbott Laboratories, Abbott Park, IL.
- Tetramethylbenzadine was purchased from Aldrich Chemical Company, Milwaukee, WI.
- Hydrogen peroxide was obtained from J.T. Baker Chemical Company, Phillipsburg, NJ.
- BBL media was obtained from Becton Dickinson Company, Franklin Lakes, NJ.
- Other reagent grade chemicals or highest possible purity were acquired from various manufacturers.

B4 Blood Collection and Processing

Donors received venipuncture with a 15-gauge needle and whole blood was collected into an empty (no preservatives nor anticoagulants) 600-mL capacity plastic bag that was placed in an ice bath to retard clot formation. A second blood specimen was collected in a 10-mL, evacuated, rubber-stoppered glass container to screen donors for HbsAg, HIV Ab, and HCV Ab. Donor units that tested positive for any of these three viruses were discarded and excluded from the pooling process. Within five to ten minutes of blood collection, the iced whole blood units were weighed and placed into a Beckman J6B refrigerated centrifuge equipped with a six-place rotor with carriers and spun at 2,200 rpm (1,500 x g) for eight minutes at 4°C. Following centrifugation, plasma was aseptically transferred from the plastic collection bag into a sterile 250-mL glass bottle equipped with a Teflon®-lined screw-cap closure. The material was held at room temperature for three to four hours to permit clot formation.

Clotted samples were centrifuged at 3,500 rpm for 18.5 minutes (2,700 x g) using a Sorval RT6000 equipped with H1008 rotor and four single-slot carriers. Sera was transferred to 250-mL Wheaton borosilicate bottles capped with Teflon®-lined screw caps and stored at 4°C.

The evacuated tube was collected from each donor immediately after the whole blood unit was used to analyze individual units for exclusion criteria. ELISA techniques using Abbott Laboratories reagents for HbsAg, HIV Ab, and HVC Ab screened each unit for positive reactivity. (See Section B5.)

Sixty 1.0-mL frozen aliquots were prepared from each serum unit selected for the pool preparation. A Wheaton Unispense set at 1.0 mL was used to prepare the aliquots in 3.0-mL glass vials, capped with Teflon®-covered gray stoppers and secured with center tear-out aluminum crimped seals. The aliquots from each individual unit were labeled and frozen at -70°C. The residual material of the individual units was used for the pool preparation. The optimal serum volume from individual units was set at 120 mL; however, 60- or 90-mL volumes were used from units that met the selection criteria but had low yield. Therefore, 44 individual serum units were included in the low/normal serum pool, 37 of which provided 120 mL, 5 gave 90 mL, and 2 gave 60 mL for a total pool volume of 5,010 mL. Similarly, 43 individual serum units were used for the high-lipid pool with 29, 10, and 4 units providing 120, 90, and 150 mL each, for a total pool volume of 4,980 mL. Both pool preparations were completed within 42 hours of the initial whole blood collection. Each pool was incubated for 18 hours at 4°C with constant mixing with a magnetic stirrer at low speed to ensure homogeneity of the final pool and allow any nonspecific agglutination or further clotting process to occur.

Following the cold incubation period, the serum pool was decanted into a 5-gal. (18.9-L) stainless steel tank. Nitrogen at low pressure (2 to 3 psi) was required for sterile filtration through a 0.22-μm hydrophilic Durapore® Millipore filter into a 6.0-L glass flask prior to final aliquoting of the pool. As with the individual serum units, 1.0-mL aliquots of the pool were dispensed with the Unispenser into 3.0-mL...
glass vials, capped, sealed, and frozen at -70 °C. The 6.0-L flask of pooled sera was maintained at 4 °C on ice and placed on a magnetic stirrer to ensure the homogeneity of the product throughout the aliquoting process. Boxes of the 1.0-mL vials of the pool were placed in a precooled -70 °C freezer. All of the sample boxes were placed in the freezer at the same time, being sure that each box was in direct contact with the metal shelf of the freezer. A total of 56 hours were required from the initial whole blood collection to completion of the aliquoting, capping, crimping, and storage of the pooled sera. The two pools were prepared within one week of each other and stored at -70 °C.

Key aspects of this approach for the preparation of two levels of lipid (cholesterol and triglyceride) are the following elements:

- Unaltered serum units (no additives).
- Fasting status of donors (minimize chylomicrons and large VLDL).
- Short time from collection to pool dispensing and freezing.
- Material maintained at 4 °C throughout the process.
- Glass vials as primary storage containers.
- Storage at -70 °C.

B5 Testing Procedures Relevant to Production of Cholesterol Pools

B5.1 Virus Testing

Individual donor units were tested for Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Surface Antigen with Abbott EIA Diagnostic kits. The readings were made on an Abbott Quantum II spectrophotometer with internal controls provided with the Abbott System test kit.

B5.2 Microbial Testing

Microbial testing was performed with BBL media. The following plates were inoculated with a sample from each pool: nutrient agar, MacConkey agar, and blood agar. Additionally, a triple sugar iron (TSI) agar tube was inoculated with each pool. This combination of media was used to rule out the presence of *Escherichia coli*, *Salmonella*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*. A *Staphylococcus* latex test was performed on colonies identified to be *Staphylococcus* to rule out *Staphylococcus aureus*.

B5.3 Analyte Testing

1. Total protein, bilirubin, A/G ratio, and glucose were tested on Hitachi 705 Automatic Chemistry Analyzer using reagents provided by the manufacturer, Boehringer Mannheim Corporation. Precical used for calibration and Precitrol (N, AbN) used as controls were manufactured by Boehringer Mannheim Corporation. The Hitachi 705 Chemistry Analyzer is maintained by the manufacturer twice a year in a preventive maintenance program. Daily controls are run for each analyte.

2. Cholesterol and triglycerides were tested on a Hitachi 705 Automatic Chemistry Analyzer using reagents provided by the manufacturer, Boehringer Mannheim Corporation. Standards and controls were frozen serum manufactured by Solomon Park Research Laboratories with target values set using the Abell-Kendall Reference Method at the Northwest Lipid Research Laboratories, University of Washington, Seattle and at the Centers for Disease Control and Prevention, Atlanta, respectively. The Hitachi 705 Chemistry Analyzer is maintained by the manufacturer twice a year in a preventive maintenance program.

Daily controls were run with cholesterol and triglyceride analyses. The Hitachi 705 was certified for cholesterol testing through the cholesterol Reference Method Laboratory Network at the Northwest...
Lipid Research Laboratories, University of Washington, Seattle. Solomon Park also participates in the ReLabs program through the Northwest Lipid Research Laboratories, University of Washington, Seattle, which assesses accuracy and precision for total and HDL-cholesterol and triglycerides on a quarterly basis. Finally, Solomon Park participates in the CAP Excel proficiency testing program for lipids.

(3) Ammonia was tested by end-point ultraviolet analysis on a Beckman DU-20 Spectrophotometer using reagents from Sigma Diagnostics. Calibration was conducted per SigmaÆs instructions. Controls were manufactured and provided by Sigma. The Beckman DU-20 Spectrophotometer is maintained by the manufacturer twice a year in a preventive maintenance program. Daily controls were run with each ammonia analysis.

(4) Hemoglobin was tested by end-point colorometric analysis on a Beckman DU-20 Spectrophotometer using reagents from Sigma Diagnostics. Standards and controls were manufactured and provided by Sigma. The Beckman DU-20 Spectrophotometer is maintained by the manufacturer twice a year in a preventive maintenance program. Daily controls were run with each hemoglobin analysis.

(5) Clotting Element Test was tested by OD readings made before and after exposing the individual unit or pool specimen to 55°C for five minutes. The readings were made on a Beckman DU-20 Spectrophotometer. The Beckman DU-20 Spectrophotometer is serviced by the manufacturer twice a year on a preventive maintenance contract.

(6) pH was monitored on a Beckman f40 pH meter using a refillable combination electrode Ag/AgCl half cell. The meter was standardized at the beginning of each run with buffer solutions with target values at pH 4.00, 7.00, and 10.00.

B5.4 Blood Typing

Blood typing was performed by agglutination using Dade reagents and red-cell controls and was done using the “tube method.”

B6 Materials Validation Results

A critical assumption that was made when combining donor units to produce serum pools was that the pool would behave similarly to individual patient specimens in the measurement process, and thus the pool could be used to establish traceability and assess measurement accuracy. To determine whether the pooling process contributed to matrix effects, the guideline was validated by preparing two serum pools according to the written specifications. The pools were evaluated for cholesterol measurement performance relative to the population of individual donor samples contributed to each pool. The results of this validation work is planned for archival publication and is therefore presented here in summary.

Two factors were considered when selecting the number of donors used to make each pool (other than serum volume):

- **The effect of an interference from one or more donors on the final pool.** The effect of an interference from one donor was estimated by assuming that bias was proportional to the donor’s serum volume contribution to the pool. If this assumption was correct, the bias introduced into the pool was the bias of the single donor divided by the total number of donors \((\text{Bias}_\text{pool} = \text{Bias}_\text{donor}/N)\). For example, if a single donor sample had a cholesterol bias of 30% due to interferences, a 1% bias in a pool comprised of 30 donors would result. Based on this assumption, a pool of at least 40 donors was selected to minimize the effect any single donor might have on the pool.
The sample size needed to estimate bias, with sufficient statistical power, in the final pool result. A statistical design was developed which permitted detection of performance differences in excess of 2% between the pool and the population of patient sera. Assuming that field methods for cholesterol measurement should perform with a CV of at least 3% (based on NCEP performance guidelines), it was determined that 40 donors are required to detect a 2% bias between the pool and donors with 90% confidence.

Based on these relationships, two pools were prepared from individual units as follows:

- **Pool 95-LI**: 44 units of 60 to 120 mL each.
- **Pool 95-LII**: 43 units of 90 to 150 mL each.

Twenty-six instrument/reagent systems representing 13 manufacturers and one reagent vendor participated in the materials validation study. Each participating manufacturer was provided with vials from the two pools and each of the donor units comprising each pool. Nineteen systems assayed all samples in a single analytical run with appropriate replication for the desired statistical power. The pools were tested 15 times, the donor units in duplicate, and two levels of controls in singlet at the beginning and end of the run. The remaining seven systems made two or more analytical runs. Results were coded so that the identities of instrument vendors were unknown.

None of the 26 instruments evaluated in this study showed a consistent bias between donor samples and serum pool cholesterol results. Bias is defined here as the difference between the observed serum pool mean and the expected mean calculated from the weighted average of the individual donor samples (bias = pool result - donor result). Pool result is the mean of all serum-pool assays. The donor result is the weighted mean of the donor sample assays. For systems with multiple runs, an additional weighting factor was computed from the controls in each run to minimize run effects. Weights were computed from the serum volumes for each donor used to create the pools. These weighted means are the “expected” values for the pools in the absence of matrix bias. All biases, with the exception of one system for Pool II, were less than the 2% criteria used to determine a statistical difference between the pools and the population of patient sera used to prepare the pools. In fact, all biases with the exception of one different system for Pool I and one different system for Pool II, were less than 1.5%. Except for the one system for Pool II, which at 2.2% was just slightly greater than the 2.0% criteria, the results in this study are sufficient to conclude that the serum pools prepared according to this guideline behave like donor samples on the systems evaluated.
B7 Certificates of Analysis for Cholesterol Pools

SOLOMON PARK RESEARCH LABORATORIES
CERTIFICATE OF ANALYSIS FOR POOLS

POOL ID # NCCLS I DATE/TIME OF POOLING 8:00 p.m./ 9/24/95

TECHNOLOGIST SM POOLING COMPLETED 11:00 p.m./ 9/24/95

TEST RESULTS:

AMMONIA: [76.6] MUST BE <100 μmol/L
INSTRUMENT: BECKMAN DU-20 METHODOLOGY: UV, ENDPT
REAGENT: SIGMA LOT #045H6189_EXP 3/96
CALIBRATION: SIGMA LOT #035H6119_EXP 3/97

pH: [8.20] MUST BE 7.6 ± 0.4
INSTRUMENT: BECKMAN † - 40 METHODOLOGY : ELECTRODE
REAGENT: N/A LOT # --- EXP ---
CALIBRATION: VWR LOT # 268_EXP 5/96

A/G RATIO: [1.37] MUST BE >1.0
INSTRUMENT: HITACHI 705 METHODOLOGY : A/ (B-A)
REAGENT: BMD LOT # --- EXP ---
CALIBRATION: PRECICAL LOT # --- EXP ---
(Calculated/NA)

GLUCOSE: [84.0] MUST BE >60.0 mg/dL
INSTRUMENT: HITACHI 705 METHODOLOGY : HEXOKINAS
REAGENT: BMD LOT #14660_EXP 2/27/96
CALIBRATION: PRECICAL LOT #XLS-96_EXP 8/17/97

MICROBIAL TESTING
NUTRIENT AGAR MUST BE <10 CFU/mL
# OF COLONIES: 0 CFU/mL no growth

BLOOD AGAR
RESULTS: 0

MACCONKEY AGAR
RESULTS: 0

TSI TUBE
RESULTS: 0

Escherichia coli _______ POS _______ X NEG
Salmonella _______ POS _______ X NEG
Staphylococcus aureus _______ POS _______ X NEG
Pseudomonas aeruginosa _______ POS _______ X NEG

Plates were run on final filtered pool as well as on unfiltered residue from pressure tank. There was no growth in either of these samples.
B7 Certificates of Analysis for Cholesterol Pools (Continued)

CLOTTING ELEMENT TEST AND FINAL O.D. 710 nm READING

INITIAL O.D. 710 nm READING [0.051] Pool I

POST 55° O.D. 710 nm READING [0.040]

FINAL UNIT O.D. 710 nm READING [0.040] MUST BE <0.5

F-ration MS (B) /MS (A) [0.34] MUST BE <2.348

F-ration MS (C) /MS (B) [1.59] MUST BE <3.020

POOL ACCEPTED X YES _____ NO IF NO CHECK HERE

FREEZING DATA:

DATE AND TIME OF INITIAL FREEZING OF POOL AND INDIVIDUAL DONOR UNITS ASSOCIATED WITH POOL 11:20 p.m. / 9/25/95

HAVE ANY VIALS BEEN EXPOSED TO TEMPERATURES OTHER THAN -70 DEGREES CELSIUS FOLLOWING INITIAL FREEZING? _____ YES X NO

IF YES, DESCRIBE TEMPERATURE AND DURATION OF EXPOSURE:

PRODUCTION/SHIPPING DATA:

DATE AND TIME PRODUCTION BEGAN 6:00 a.m. / 9/23/95 (FIRST DONOR DRAW)

DATE AND TIME PRODUCTION ENDED 12:48 a.m. / 9/26/95 (PRODUCTS FROZEN)

DATE AND TIME PRODUCT SHIPPED NA / NA

FORM COMPLETED BY: Patric A. Clapshaw Sci. Director NAME TITLE

FORM VERIFIED BY: Sheila McGrath MLT (ASCP) NAME TITLE
B7 Certificates of Analysis for Cholesterol Pools ( Continued )

SOLOMON PARK RESEARCH LABORATORIES
CERTIFICATE OF ANALYSIS FOR POOLS

POOL ID #  NCCLS II

DATE/TIME OF POOLING  9:00 p.m./ 10/1/95

TECHNOLOGIST  SM

POOLING COMPLETED  11:20 p.m./ 10/1/95

TEST RESULTS:

AMMONIA: [ 49.9 ]  MUST BE <100 µmol/L
INSTRUMENT: BECKMAN DU-20
REAGENT: SIGMA
CALIBRATION: SIGMA

pH: [ 8.18 ]  MUST BE 7.6 ± 0.4
INSTRUMENT: BECKMAN
REAGENT: N/A
CALIBRATION: VWR

A/G RATIO: [ 1.28 ]  MUST BE >1.0
INSTRUMENT: HITACHI 705
REAGENT: BMD
CALIBRATION: PRECICAL

GLUCOSE: [ 86 ]  MUST BE >60.0 mg/dL
INSTRUMENT: HITACHI 705
REAGENT: BMD
CALIBRATION: PRECICAL

MICROBIAL TESTING

NUTRIENT AGAR  MUST BE <10 CFU/mL
# OF COLONIES: 0  CFU/mL  no growth

BLOOD AGAR
RESULTS: 0

MACCONKEY AGAR
RESULTS: 0  Plates were run on final filtered pool as well as on unfiltered residue from pressure tank. There was no growth in either of these samples.

TSI TUBE
RESULTS: 0

Escherichia coli  POS    X  NEG
Salmonella  POS    X  NEG
Staphylococcus aureus  POS    X  NEG
Pseudomonas aeruginosa  POS    X  NEG
B7  Certificates of Analysis for Cholesterol Pools (Continued)

CLOTTING ELEMENT TEST AND FINAL O.D. 710 nm READING

INITIAL O.D. 710 nm READING \[0.062\] Pool II

POST 55° O.D. 710 nm READING \[0.058\]

FINAL UNIT O.D. 710 nm READING \[0.058\] MUST BE <0.5

F-ration MS (B) /MS (A) \[0.65\] MUST BE <2.348

F-ration MS (C) /MS (B) \[1.58\] MUST BE <3.020

POOL ACCEPTED \[X\] YES \[\] NO IF NO, CHECK HERE

FREEZING DATA:

DATE AND TIME OF INITIAL FREEZING OF POOL AND INDIVIDUAL DONOR UNITS ASSOCIATED WITH POOL 11:00 p.m. / 10/2/95

HAVE ANY VIALS BEEN EXPOSED TO TEMPERATURES OTHER THAN -70 DEGREES CELSIUS FOLLOWING INITIAL FREEZING? \[\] YES \[X\] NO

IF YES, DESCRIBE TEMPERATURE AND DURATION OF EXPOSURE:

PRODUCTION/SHIPPING DATA:

DATE AND TIME PRODUCTION BEGAN 6:00 a.m. / 9/30/95

DATE AND TIME PRODUCTION ENDED 1:10 a.m. / 10/2/95

DATE AND TIME PRODUCT SHIPPED NA / NA

FORM COMPLETED BY: Patric A. Clapshaw Sci. Director

NAME TITLE

FORM VERIFIED BY: Sheila McGrath MLT (ASCP)

NAME TITLE
Summary of Comments and Subcommittee Responses


Abstract

1. Abstract (page i, line 4) suggestion to add: “...commutable for cholesterol measurement, with the purpose of assigning values to calibrators at the level of the manufacturer’s measurement procedures and/or routine measurement procedures.”

• The subcommittee agrees with the comment in principle. The Abstract has been revised to provide additional clarification.

Foreword

2. Foreword (page xiii, first paragraph, line 1): it is presumed to be known that elevated blood cholesterol is harmful to the human health condition. Suggestion to add: “…blood cholesterol, purportedly a threat to the human health condition worldwide, has been a primary objective...etc.”

• An introductory statement has been added to indicate the world health problem of elevated cholesterol and the risk for heart disease.

Section 3

3. Page 1 refers to “Universal Precautions.” At the recent NCCLS conference in Toronto I was interested to learn that it is the intention of the CDC to replace this term with “Standard Precautions.” Based on several discussions, my understanding is that NCCLS would like to follow the CDC’s lead and revise appropriate sections of guidelines and standards as they are developed or come up for review.

• CDC has developed new guidelines (Standard Precautions) for use in the care of patients in acute-care hospitals. The new "Standard Precautions" synthesize the major features of Universal Precautions and Body Substance Isolation practices. Standard Precautions cover the transmission of any pathogen and thus are more comprehensive than Universal Precautions, which are intended to apply only to transmission of blood-borne pathogens. The subcommittee agrees that Section 3 should be retitled "Standard Precautions.” The section has been revised accordingly.

Section 4

4. The term: Reference Material(s): e.g., title, keywords, foreword etc. I submit to the committee: to use the term calibrator or calibration material. Often the term is also used for control material for the purpose of verification of trueness. To mix the two meanings creates confusion; I invite the committee to screen the text and see where which meaning is meant. I do think that Reference Material should not be used in the sense of “control material.”

• The use of the term is not ambiguous. The definition provided is derived directly from ISO vocabulary, as published in ISO Guide 30: 1992 and VIM: 1993, 6.13. This reference citation has been added in the text of the definition. ISO includes both controls and calibrators under the general heading of reference materials. A given material may be employed with a particular procedure for either one purpose or the other (calibration or control), but can never be used for both purposes within that particular procedure. The materials prepared in accord with this guideline may be used for lesser purposes, such as quality control, if desired, but the resulting quality of the materials allows for higher level use.
5. The terms: Accuracy, trueness and precision: throughout the document, but particularly in the Foreword and Scope. All three terms are qualitative ones; e.g., high/low. The quantitative expression of trueness is percentage bias, and of precision, e.g., the percentage CV (imprecision). In this case the term “trueness” can be applied as the analyte which we want to measure – cholesterol – physico-chemically is fully defined, and the result of measurement can be expressed in terms of moles, i.e., SI units. I submit to the committee to screen the text for the occurrence of the term “accuracy,” “accurate” where actually – in many cases – trueness or true (value) is meant. Please harmonize the terminology used in your document with the upcoming ISO/CEN documents on traceability.

- This is an excellent suggestion and the subcommittee agrees with the comment. In order for NCCLS documents to be accepted globally, terminology should conform to ISO guidelines. However, accuracy, accurate are historically ingrained into the scientific vocabulary in the U.S. and are generally understood to mean the same as trueness, true. Trueness, true is the preferred ISO terminology; thus, the text has been changed accordingly. However, accuracy, accurate have been retained in parentheses throughout the document to maintain clarity of presentation. A discussion has been added in the definition section indicating that trueness is the ISO-recommended terminology. Appropriate changes are introduced in the Foreword and the Scope.

6. The term: Commutability: this term is difficult to define. But, see the ISO/CEN documents on traceability for another – more elaborate – definition. Perhaps, the committee wants to incorporate that definition next to the one offered in the NCCLS document (perhaps a note?).

- The ISO definition for commutability of a material has been added as a note to the definition of commutable in Section 4, Definitions.

7. A hemolyzed specimen may show minimal color change. It should be noted that the color change is proportional to the extent of hemolysis.

- The statement is correct but a revision in the definition of hemolysis is not required.

Section 5.1

8. Pool preparation: 2nd paragraph: as this document might become universally applicable: a sentence about the legal issues of collection blood donations might be appreciated; it should be according to local legislation; the procedure should be transparent and informed consent from the donor should be obtained.

- Section 6.1, Donor Selection, has been revised to indicate the need for informed consent from each donor.

9. Pool preparation; 4th paragraph, line 10: sterile glass bottle: is the committee sure that “sterile” is actually meant, or will aseptic do as well? (Within CEN the debate on “sterile” and “aseptic” is quite heated). Cf. also page 10 of NCCLS document with the flowchart, and clause 7, (6), 7. (13).

- In Section 7, the glass bottles, containers, and stir bars used in the blood processing steps (3), (6), and (12) were sterilized by autoclaving, and therefore the term sterile used in this context is appropriate. A sentence for clarification has been added to Section 5.1, Pool Preparation, 6th paragraph.

10. Pool preparation; 5th paragraph, line 7: predominate = predominant?

- The subcommittee believes that either term is acceptable.
11. Pool preparation; 5th paragraph, line 11-12: “This peak was of minor consequence in all other samples.” Is the committee sure that it was of minor consequence? How do you know? Potential interference.

- It is known that lipoproteins undergo oxidation and degrade. It has also been shown that phthalate esters can promote lipoprotein oxidation. For convenience and practical reasons, collection of blood in plastic bags is the recommended industry standard. To minimize contact with the plastic bag, the collected blood was carefully transferred to glass as quickly as possible after the bags were centrifuged to separate the plasma from the cells. The two pools prepared in accordance with this guideline were compared with blood products collected and stored long-term in plastic bags. Compared to the stored blood bank product which gave a major phthalate ester peak by GC/MS, the two pools prepared in accordance with this guideline contained only trace amounts of detectable phthalates. Actual interference by the presence of any phthalate esters was not evaluated. It was assumed that, because the levels observed in the two study pools were so small, the impact on the materials was insignificant. The text has been revised to indicate that the potential for interference by the presence of phthalate esters was not investigated.

12. Pool preparation; 11th paragraph: when making such materials – for other purposes and quite a long time ago - I was accustomed to snap-freeze the small volume aliquots (see B.1. aliquots of 1 mL). The mixture may be crude acetone/alcohol – dry ice mixture. The liquid is frozen within 15 minutes. Suggestion that the committee considers to recommend this procedure. Please note: if snap-freezing is mentioned, it is recommended to add a note to the effect that labels should be applied after this procedure is done (labels/felt-pen writing is affected by acetone/alcohol).

- The subcommittee appreciates the comments and experience provided by the reviewer. The procedure detailed in this guideline only describes what was done and what worked. The subcommittee cannot speculate beyond this point as to what alternative approaches might be successful. The procedure described in the guideline is more practical for a manufacturing setting when preparing large pools. It would seem that the procedure using acetone/alcohol-dry ice mixture is more appropriate for freezing small pools prepared in a research setting.

13. Pool preparation; 12th paragraph: suggestion to print the sentence “Material should not be refrozen” in bold print.

- The sentence has been changed to bold print.

14. Pool preparation; 3rd paragraph: From our experience an interference of a single donor is sometimes not linear after dilution with sera of other donors. Therefore, in this case you cannot minimize the bias in a linear way as proposed. In contrary, it may happen that the opposite will be observed.

- It is certainly possible that some interferences may be nonlinear, and would not be minimized by dilution. The subcommittee selected this admittedly simplistic model merely to provide a means to statistically estimate the minimum number of donors required for the pools. Protein modification or precipitation may occur due to cross-contamination with one or more donor units. The cold incubation period of 18 hours should handle this; however, the unpredictability of interferences underscores the importance of performing commutability verification studies on each pool, as part of the routine quality assurance process, prerequisite to releasing a given pool for use as a reference material. This point has been added to the text in Section 5.2, Validation of Performance and Commutability.

Section 5.2

15. Validation of performance and commutability; 3rd paragraph, line 2: “….. panel of individual human serum samples.” Fresh, frozen, old samples?
Although a full panel of fresh human sera is the ideal, it may not be practical to obtain a broad range of specimens covering the reportable range of the method/procedure in a time frame that would support such a study. A statement has been added to the text in Section 5.2 which discusses the practical implications of this problem. When specimens need to be preserved to support these studies, careful storage of the specimens at 70 ° Celsius is required.

Section 6.1

16. Donor selection: “…concentration levels ….”: how many levels are desired? Should the levels cover the measuring range claimed by the manufacturer? This will be required in the ISO/CEN standard on traceability.

The guideline outlines procedures for selecting, processing, and combining donor units to prepare frozen serum pools for cholesterol measurement. Specification of concentration levels of resulting pools prepared according to the guideline is outside the context and purpose of this document. The two concentration levels were selected to have a normal cholesterol level pool and an elevated cholesterol level pool based on the NCEP cholesterol medical decision points for coronary heart disease risk. However, the guideline should be applicable to the preparation of cholesterol pools at all concentration levels. The number of pools and levels prepared would be based on the needs of the end user. A practical limitation to this process is the collection of sufficient donor units with values at the extremes of clinical interest to prepare sufficiently large pools.

The proposed requirement in the ISO draft standard on traceability (ISO/CD 17511; 1998, 4.3.2) covers the situation where a set of human samples is used as a secondary calibrator to ensure commutability of a reference material. In this case the set of samples should span the measuring interval of the method.

Section 7

17. (14): If possible, in the laboratory, we would like to recommend to freeze the pool with liquid air (shock-frozen pool). If the pool is frozen slowly, lipid particles are built. In dry chemistry these particles may be filtered by the separation layer with the result of a bias.

See response to Comment 14.

Appendix B

18. B.2.3. Does the committee want to make a statement, please, about which reference measurement procedures are recommended to assign values for cholesterol and triglycerides?

The Laboratory Standardization Panel of the NCEP recommends that all total, HDL, and LDL cholesterol and triglyceride results be standardized and traceable to the reference methods at the CDC. Therefore, if assigned, reference values should be established by the CDC reference methods.

Reference values were not needed as part of this project. The only values needed were the cholesterol values determined by each respective instrument system being evaluated for matrix effects from pooling.

19. B.3.2. Reagents: reagents for syphilis testing are not mentioned (see 6.2 (1)).

The donor units were not tested for syphilis. Reference to syphilis testing in Section 6.2 has been deleted.
20. B.4. Blood collection and processing; 1st paragraph, line 4. Instead of “specimens” it is suggested to use “donations.” The term “specimen” is regarded as ambiguous.

- The term specimens is replaced with donor units.
  In addition, the term patient sample has been replaced with human sample throughout the document.

21. B.5.3. and B.7.: it seems to me that a “control material,” called Precical, and other control materials by Sigma (for ammonia) and VWR (for pH) were used to calibrate the reagents and instruments. Control materials should – in my opinion – not be used for calibration. Perhaps I am mistaken; however, could this be clarified by the committee?

- Different calibrator and controls were used for total protein, bilirubin, A/G ratio, and glucose. Specifically, Precical from Boehringer Mannheim Corporation (BMC) was used for calibration for total protein, bilirubin, A/G ratio, and glucose; and Precitrol (N, AbN) from BMC was used as controls. The text has been revised to indicate the use of Precitrol as a control. Separate and different calibrator and controls were provided by Sigma for the determination of ammonia.

22. B.6, last paragraph: It is concluded that the serum pools tested behaved like donor samples on the 26-instrument/reagent systems. This appears to contradict the “exception” statement on lines 8 and 9.

- The summary paragraph was revised to clarify the conclusions.
Related NCCLS Publications*

M29-A  Protection of Laboratory Workers from Instrument Biohazards and Infectious Disease Transmitted by Blood, Body Fluids, and Tissue; Approved Guideline (1997). This document provides guidance on the risk of transmission of hepatitis viruses and human immunodeficiency viruses in any laboratory setting; specific precautions for preventing the laboratory transmission of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure.

NRSCL8-A  Terminology and Definitions for Use in NCCLS Documents; Approved Standard (1998). This document provides standard definitions for use in NCCLS standards and guidelines, and for submitting candidate reference methods and materials to the National Reference System for the Clinical Laboratory (NRSCL).

* Proposed- and tentative-level documents are being advanced through the NCCLS consensus process; therefore, readers should refer to the most recent editions.
NOTES